Back to News
Market Impact: 0.35
Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Omeros Corporation said the EMA’s Committee for Medicinal Products for Human Use issued a negative opinion on its marketing authorization application for narsoplimab after re-examination. The provided article text does not specify the rationale or any further regulatory steps.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
OMER-0.80
More News
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Stock fixing scandal could see Turkish companies frozen out of global indexes
- All the news about the iPhone Duo
- The Tesla Roadster should go into production in 2028, but don't get your hopes up
- MSCI Ignites Indonesia Market Reckoning After Months of Warnings